Recently, Eph-targeted therapeutic strategies have also embraced therapeutic proteins, as radiosensitizers in cancer treatment (sEphB4-HAS, [134]) and as Eph-targeted cytotoxins (eA5-PE38QQR, [135]). Here, EPHA1 is linked to cancer.